McKesson Applauds DOJ Policy Change on Opioid Quotas
SAN FRANCISCO--(BUSINESS WIRE)--McKesson Corporation today praised the U.S. Department of Justice’s decision to exercise its authority to reduce opioid production if the agency believes a particular drug is highly diverted. The annual opioid production quota determines the total amount of controlled substances that can be produced each year. This new rule calls on the Drug Enforcement Administration to carefully assess which drugs are being diverted – an important part of the effort to curb opioid misuse and abuse.”. McKesson is deeply concerned by the impact the opioid epidemic is having on families and communities across the nation—and is committed to being part of the solution.